Chief Executive Officer and board member of MiMedx Group, Inc. (Nasdaq: MDXG), a leader in placental biologics, since January 2024 President, Chief Executive Officer and a director of BioTelemetry, Inc. (Nasdaq: BEAT) from June 2010 until its sale to Royal Philips in February 2021 President and Chief Executive Officer of Home Diagnostics from 2008 to 2010 President and Chief Executive Officer of CCS Medical from 2003 to 2008 Various offices of Bayer AG from 1994 to 2003 Recent Public Company Board Service Neuronetics, Inc. (Nasdaq: STIM), a medical technology company focused on transforming patient lives with the best neurohealth therapies in the world, from January 2023 to May 2024 Education M.B.A. in International Finance from George Washington University B.S. in Accounting from West Chester University Relevant Skills Medical Devices/Pharmaceutical Experience, R&D/Innovation Expertise, Commercialization/Marketing Expertise, M&A/Business Development Expertise, Financial Oversight/Accounting Expertise, Regulatory Expertise, and International/Global Business Experience gained during his nearly 30 years in the medical device and healthcare industries, including his significant executive leadership experience, global brand management, marketing, sales and product development, operations Public Company Governance/Corporate Responsibility Expertise obtained through his significant experience serving on boards of directors, including the board of publicly held companies